Immuron IMRN
NASDAQ IMRN
$0.97 -0.05 (-4.90%)
At close: Oct 21, 2026 · 4:00 PM EDT

Immuron (IMRN) Current Deferred Revenue (2017 - 2023)

Updated

Immuron (IMRN) reported Current Deferred Revenue of $466,646 for fiscal Q4 2023 (quarter ended Jun 30, 2023).

Analysis

Immuron (IMRN) Current Deferred Revenue (2017 - 2023) Analysis & Trends

At the end of FY2023 (ended Jun 30, 2023), Immuron posted Current Deferred Revenue of $470,176.

  • The fiscal Q4 2023 figure ranks as the lowest quarterly Current Deferred Revenue since fiscal Q4 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Immuron 7.32 Mn -9.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 462,184.91
Dec 31, 2017 14,917.50
Sep 28, 2017 15,025.48
Aug 31, 2017 19,139.00
Jun 30, 2017 14,708.73
API Access

Immuron Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=IMRN&period=max&api_key=YOUR_API_KEY